MFMarcos F. Fondevila

Marcos F. Fondevila

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marcos F. Fondevila has a total of 210 co-authors. Here are the top co-authors by number of shared publications:

  • Natália da Silva Lima

    Department of Physiology, CIMUS, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain

    8 shared publications
  • Ruben Nogueiras

    Universidade de Santiago de Compostela-Instituto de Investigation Sanitaria, Santiago de Compostela, Spain

    8 shared publications
  • Ana Senra

    Department of Physiology, CiMUS, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain

    7 shared publications
  • Carlos Dieguez

    Department of Physiology, CiMUS, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain

    6 shared publications
  • Eva Novoa

    Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain; CIBER Fisiopatologia de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15782, Spain

    6 shared publications
  • Miguel López

    Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain

    6 shared publications

Latest Publications

  • Open Access

    Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial

    by Mijra Koning, Artemiy Kovynev, Marcos F. Fondevila, Eliza J. M. Ruhe, Michiel C. Mommersteeg, Christian Ramakers, Barbara A. Hutten, Bart Verwer, Marije Vlug, Teaco Kuiper, et al.

    Cellular senescence plays an important role in hepatic inflammation and fibrosis1,2,3. However, whether senescence represents a potential therapeutic target in humans with metabolic dysfunction-associated steatohepatitis (MASH) remains unexplored. Here we report the results of a phase-2, double-blind, randomized, placebo-controlled trial of intermittent senolytic therapy with dasatinib plus quercetin (D + Q) in participants with fibrotic MASH. Thirty-one participants (median age 56 years; 76% male; 58% with type 2 diabetes) were randomized (1:1) to receive D + Q (dasatinib 100 mg per day plus quercetin 1,000 mg per day) or placebo for three consecutive days per week over 3 weeks, repeated across three 7-week cycles. The primary endpoint, ≥1 stage fibrosis improvement without MASH worsening on paired liver biopsies, is achieved in 47% of D + Q-treated participants versus 7% with placebo (P = 0.02). MASH resolution occurs more frequently with D + Q than placebo (53% versus 7%; P = 0.02), with a greater reduction in NAFLD Activity Score (−1.43 ± 1.22 versus −0.39 ± 0.77; P = 0.012). Single-nucleus RNA sequencing demonstrates decreased senescence and fibrotic gene signatures and reduced fibrogenic cell populations in the D + Q group. Although adverse events are more frequent in the D + Q group (82% versus 43%), these are all self-limiting. Overall, this proof-of-principle trial supports the need for future trials of senolytic therapy in fibrotic MASH. ClinicalTrials.gov identifier: NCT05506488.


  • Faecal Cathepsin B and S Are Associated With Liver Disease Severity and Adiposity in MASLD

    by Aenne Harberts, Marcos F. Fondevila, Henriette Kreimeyer, Takao Miwa, Sonja Lang, Münevver Demir, Bernd Schnabl

    Background & Aims: Dysregulation of hepatic cathepsins contributes to metabolic dysfunction‐associated steatotic liver disease (MASLD) by promoting inflammation, apoptosis, and fibrosis. However, the role of intestinal cathepsins in MASLD has not been investigated. Given the central role of the gut‐liver axis in disease progression, this represents an important knowledge gap. Methods: Faecal cathepsin B and S activity was measured in 95 patients with MASLD and 18 healthy controls. Cathepsin activity was correlated with liver disease severity, metabolic parameters, and gut microbiome composition. Results: Faecal cathepsin B and S activity was higher in patients with MASLD than in healthy controls. Cathepsin B activity was further increased in patients with metabolic dysfunction‐associated steatohepatitis. Cathepsin B and S activity correlated with serum transaminases and hepatic steatosis, while cathepsin B activity was additionally associated with liver stiffness. Cathepsin B and S activity correlated with adiposity but showed no associations with other metabolic dysfunction‐related parameters. Moreover, gut microbiome composition differed between patients with low vs. high faecal cathepsin B or S activity, respectively. Conclusion: Increased faecal cathepsin B and S activity is associated with liver disease severity and adiposity in MASLD and is linked to alterations of the gut microbiome, suggesting a potential role of intestinal cathepsins in gut‐liver axis dysfunction.


  • Macrophage-derived cathepsin B disrupts intestinal tight junctions through occludin degradation and promotes alcohol-associated liver disease

    by Marcos F. Fondevila, Henriette Kreimeyer, Cynthia L. Hsu, Joaquin Tamargo-Azpilicueta, Le Z. Day, Marina Gritsenko, Kwame Attah, Noemí Cabré, Aenne Harberts, Fernanda Raya Tonetti, et al.


  • Open Access

    Inhibition of hepatic p63 ameliorates steatohepatitis with fibrosis in mice

    by Marcos F. Fondevila, Eva Novoa, Uxia Fernandez, Valentina Dorta, Tamara Parracho, Henriette Kreimeyer, Maria Garcia-Vence, Maria P. Chantada-Vazquez, Susana B. Bravo, Begoña Porteiro, et al.


  • Open Access

    Mitochondrial antiviral signaling protein enhances MASLD progression through the ERK/TNFα/NFκβ pathway

    by Eva Nóvoa, Natália da Silva Lima, Maria J. Gonzalez-Rellan, Maria D.P. Chantada-Vazquez, Joanne Verheij, Amaia Rodriguez, Eva M. Esquinas-Roman, Marcos F. Fondevila, Mirja Koning, Uxia Fernandez, et al.

    Background and Aims: Mitochondrial antiviral signaling protein (MAVS) is a critical regulator that activates the host’s innate immunity against RNA viruses, and its signaling pathway has been linked to the secretion of proinflammatory cytokines. However, the actions of MAVS on inflammatory pathways during the development of metabolic dysfunction–associated steatotic liver disease (MASLD) have been little studied. Approach and Results: Liver proteomic analysis of mice with genetically manipulated hepatic p63, a transcription factor that induces liver steatosis, revealed MAVS as a target downstream of p63. MAVS was thus further evaluated in liver samples from patients and in animal models with MASLD. Genetic inhibition of MAVS was performed in hepatocyte cell lines, primary hepatocytes, spheroids, and mice. MAVS expression is induced in the liver of both animal models and people with MASLD as compared with those without liver disease. Using genetic knockdown of MAVS in adult mice ameliorates diet-induced MASLD. In vitro, silencing MAVS blunts oleic and palmitic acid–induced lipid content, while its overexpression increases the lipid load in hepatocytes. Inhibiting hepatic MAVS reduces circulating levels of the proinflammatory cytokine TNFα and the hepatic expression of both TNFα and NFκβ. Moreover, the inhibition of ERK abolished the activation of TNFα induced by MAVS. The posttranslational modification O-GlcNAcylation of MAVS is required to activate inflammation and to promote the high lipid content in hepatocytes. Conclusions: MAVS is involved in the development of steatosis, and its inhibition in previously damaged hepatocytes can ameliorate MASLD.


  • Open Access

    p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway

    by Marcos F. Fondevila, Eva Novoa, Maria J. Gonzalez-Rellan, Uxia Fernandez, Violeta Heras, Begoña Porteiro, Tamara Parracho, Valentina Dorta, Cristina Riobello, Natalia da Silva Lima, et al.


  • Open Access

    Hepatic p63 regulates glucose metabolism by repressing SIRT1

    by Maria J Gonzalez-Rellan, Eva Novoa, Natalia da Silva Lima, Amaia Rodriguez, Christelle Veyrat-Durebex, Samuel Seoane, Begoña Porteiro, Marcos F Fondevila, Uxia Fernandez, Marta Varela-Rey, et al.

    Objective p63 is a transcription factor within the p53 protein family that has key roles in development, differentiation and prevention of senescence, but its metabolic actions remain largely unknown. Herein, we investigated the physiological role of p63 in glucose metabolism. Design We used cell lines and mouse models to genetically manipulate p63 in hepatocytes. We also measured p63 in the liver of patients with obesity with or without type 2 diabetes (T2D). Results We show that hepatic p63 expression is reduced on fasting. Mice lacking the specific isoform TAp63 in the liver (p63LKO) display higher postprandial and pyruvate-induced glucose excursions. These mice have elevated SIRT1 levels, while SIRT1 knockdown in p63LKO mice normalises glycaemia. Overexpression of TAp63 in wild-type mice reduces postprandial, pyruvate-induced blood glucose and SIRT1 levels. Studies carried out in hepatocyte cell lines show that TAp63 regulates SIRT1 promoter by repressing its transcriptional activation. TAp63 also mediates the inhibitory effect of insulin on hepatic glucose production, as silencing TAp63 impairs insulin sensitivity. Finally, protein levels of TAp63 are reduced in obese persons with T2D and are negatively correlated with fasting glucose and homeostasis model assessment index. Conclusions. These results demonstrate that p63 physiologically regulates glucose homeostasis.


  • Open Access

    Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis

    by Marcos F. Fondevila, Uxia Fernandez, Violeta Heras, Tamara Parracho, Maria J. Gonzalez-Rellan, Eva Novoa, Begoña Porteiro, Cristina Alonso, Rebeca Mayo, Natalia da Silva Lima, et al.


  • Open Access

    Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function

    by Natália da Silva Lima, Marcos F. Fondevila, Eva Nóvoa, Xabier Buqué, Maria Mercado-Gómez, Sarah Gallet, Maria J. González-Rellan, Uxia Fernandez, Anne Loyens, Maria Garcia-Vence, et al.